1. Introduction {#sec0005}
===============

Colorectal cancer (CRC) is the third leading cause of cancer deaths in the United States [@bib0005]. Nearly 20% of patients are found to have metastatic disease at the time of diagnosis [@bib0010]. The American Society of Clinical Oncology (ASCO) published guidelines in 2009 recommending all patients with metastatic colorectal cancer (mCRC) receive *KRAS* testing to guide anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MoAb) treatment [@bib0015]. Approximately 40--60% of colorectal cancers harbor a *KRAS* mutation \[[@bib0020], [@bib0025], [@bib0030]\]. This activating missense mutation was previously identified at codons 12 and 13, and most recently exons 3 and 4 [@bib0035]. Stage IV CRC patients with wild-type *KRAS* status demonstrate improved progression-free survival (PFS), objective response and overall survival (OS) after receiving chemotherapy in combination with anti-EGFR MoAb therapy, while those with *KRAS* mutations do not benefit from cetuximab or panitumumab \[[@bib0040], [@bib0045], [@bib0050], [@bib0055], [@bib0060], [@bib0065], [@bib0070]\].

Since the publication of the 2009 ASCO guidelines, recent literature has shown increased physician awareness of the need for *KRAS* testing and increased testing rates [@bib0075]. However, 50% or more of eligible patients do not receive the test \[[@bib0030], [@bib0080], [@bib0085], [@bib0090]\]. Various underserved populations such as rural residents, Hispanics, American Indians and elderly patients often have inferior oncologic outcomes and reduced access to cancer care \[[@bib0095], [@bib0100], [@bib0105], [@bib0110], [@bib0115]\]. It remains unclear if differences in genomic testing rates exist between sexes, ancestral groups, and place of residence. In 2010, New Mexico was found to have the highest rates of *KRAS* testing out of 18 registries in the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) program [@bib0090]. New Mexico, a multi-cultural state with a large proportion of rural areas presents an ideal setting to assess disparities in *KRAS* testing.

This study aimed to assess for disparities in *KRAS* testing and mutational status in the state of New Mexico, as well as to characterize testing trends over time. We hypothesized that certain population subgroups with mCRC, including older patients, racial/ethnic minorities and rural residents would be less likely to receive guideline-based testing.

2. Materials and methods {#sec0010}
========================

2.1. Patient cohort and variables {#sec0015}
---------------------------------

This investigation was conducted with existing records from the population-based New Mexico Tumor Registry (NMTR), a founding member of the NCI's SEER Program that has continuously participated in the SEER Program since 1973. Eligible cases were defined as New Mexico residents diagnosed with CRC (International Classification of Disease for Oncology-Third Edition (ICDO-3) anatomic site codes C18.0-C20.9 and C26.0) during calendar years 2010--2013. This time-period represents the first four full years that *KRAS* testing was documented in NMTR and in the SEER Program. The analysis was restricted to individuals with malignant CRC (ICDO-3 behavior code 3); individuals with benign and in-situ disease were excluded from the analysis. Cases of lymphoma (ICOD-3 histology codes 9590--9992), Kaposi Sarcoma (ICDO-3 histology code 9140) and mesothelioma (ICDO-3 histology codes 9050--9055) were also excluded from the analysis. Because of the relatively small number of CRC cases diagnosed among African Americans, Asians, and other racial/ethnic groups in New Mexico, this analysis was restricted to non-Hispanic Whites, Hispanics, and American Indians. Analysis of the predictors of KRAS testing was further restricted to individuals with AJCC Stage IV disease.

Performance of *KRAS* testing was documented from specific statements in medical records and was coded according to standards promulgated by the SEER Program. Individuals were considered to have been tested for *KRAS* if results were classified as "abnormal" or "normal". If the medical record indicated that the test had been ordered, but the result was not documented in the chart, cases were classified as not having been tested for *KRAS*. The definitions of *KRAS* testing and results are consistent with those utilized in a previous analysis of SEER Program data [@bib0090].

Variation in KRAS testing was assessed by several patient characteristics, including age at diagnosis (\<40, 40--64, and 65+ years), race/ethnicity (American Indian, Hispanic, and non-Hispanic white), calendar year of diagnosis (single years 2010--2013), sex (female, male), urban vs. rural place of residence at time of diagnosis (based on census-tract of residence) and per-capita income (quartiles, based on census tract of residence). This investigation was approved by the University of New Mexico Human Research Protections Office.

2.2. Statistical analysis {#sec0020}
-------------------------

Receipt of *KRAS* testing was assessed for each of the above-listed patient characteristics with chi-squared tests and by univariable logistic regression. Multivariable logistic regression was used to assess receipt of *KRAS* test for each patient characteristic while simultaneously adjusting for all other characteristics. All statistical tests were two-sided and assessed at an alpha level of p \< 0.05. All statistical analyses were conducted with standard modules of the Statistical Analysis System (Version 9.4, SAS Institute, Cary, NC).

3. Results {#sec0025}
==========

Overall, 3,142 patients were diagnosed with CRC in New Mexico from 2010 to 2013. Baseline patient and tumor characteristics are shown in [Table 1](#tbl0005){ref-type="table"}. AJCC 7th edition [@bib0120] stage of disease at the time of diagnosis was distributed as follows: 23.7% (n = 743) were stage I, 21.6% (n = 678) were stage II, 24.7% (n = 775) stage III and 20.3% (n = 637) stage IV. Unknown stage constituted 9.8% (n = 308) of patients. As expected, *KRAS* testing was significantly higher in stage IV cases (38.5%; p = 0.0001), though guideline discordant testing was observed stage III (8.5%), stage II (3.2%) and stage I (1.2%) ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1Frequency of *KRAS* testing by AJCC 7th edition staging, shown by number of incident cases and percentage. The majority of testing was performed in stage IV patients as expected, though a total of 13.1% of patients in stage I through III also received *KRAS* testing.Fig. 1Table 1Selected characteristics of incident CRC cases diagnosed among adult residents of New Mexico during the time period 2010-2013.Table 1CharacteristicCategoryNumber of CasesPercent of TotalAncestryNon-Hispanic White1,70454.23Hispanic1,11735.55American Indian2186.94Other1033.28SexMale1,69053.79Female1,45246.21Age at Diagnosis21-39 years752.3940-64 years1,29541.2265+ years1,77256.40Anatomic Sub-SiteRight Colon1,16737.14Left Colon75223.93Overlapping Regions of Colon230.73Colon, Not Otherwise Specified2407.64Rectum & Recto-Sigmoid Junction96030.55AJCC StageI74323.65II67821.58III77524.67IV63720.27Unknown3099.83SurgeryYes2,30473.33No70522.44Unknown1334.23RadiationYes43513.84No2,54581.00Unknown1625.16Place of ResidenceUrban2,03064.61Rural1,10635.20Unknown60.19

3.1. *KRAS* testing in stage IV patients {#sec0030}
----------------------------------------

[Table 2](#tbl0010){ref-type="table"} summarizes rates of *KRAS* testing in stage IV non-Hispanic white, Hispanic, and American Indian CRC patients. After adjusting for age, sex, ancestry, area of residence and year of testing, younger patients (ages 22--39 and 40--64 years) were more likely to receive testing than patients 65 years and older (p \< 0.0001). There were no testing disparities with regard to sex (p = 0.669) and ancestry (p = 0.378). Patients living in an urban area were more likely to receive *KRAS* testing than patients living in rural place of residence (41.8% vs. 31.9%, p = 0.017). A modest increase in *KRAS* testing rates among mCRC patients was observed from 2010 to 2013 (34.2% to 43.6%) though this was not statistically significant.Table 2Multivariable analysis of *KRAS* testing rates in Stage IV Colorectal Cancer.Table 2Number of cases, totalTested for KRAS, n (%)Adjusted\*\* Odds Ratio 95% CIPSex Male331130 (39.3)1.00Reference (Ref)0.669 Female282106 (37.6)0.880.63--1.24Age (years) 22-391912 (63.2)1.00Ref\<0.0001 40-64284141 (49.7)0.620.23--1.63 65+31083 (26.8)0.220.05--0.59Ethnicity Non-Hispanic White325126 (38.8)1.00Ref0.378 Hispanic24698 (39.8)1.040.63--1.71 American Indian4212 (28.6)0.710.30--1.68Year of diagnosis 201015854 (34.2)1.00Ref0.167 201115553 (34.2)1.000.61--1.61 201216068 (42.5)1.420.88--2.27 201314061 (43.6)1.410.87--2.28Place of residence Urban409171 (41.8)1.00Ref0.017 Rural20465 (31.9)0.670.45--0.98Annual income, per capita (census tract) \$5,051 − \$15,65615352 (34.0)1.00Ref0.618 \$15,662 − \$23,03415362 (40.5)1.480.88--2.48 \$23,126 − \$32,04215360 (39.2)1.270.68--2.35 \$32,138 − \$84,62015261 (40.1)1.210.63--2.34[^1][^2]

3.2. Difference in *KRAS* mutational status of stage IV patients {#sec0035}
----------------------------------------------------------------

Of the stage IV CRC patients who received *KRAS* testing, 43.3% had a missense mutation. There were no significant differences in rates of wild-type versus mutant status when examined by age (p = 0.693), sex (p = 0.182), ancestry (p = 0.774), year of diagnosis (p = 0.628), per capita income (p = 0.870) or geographic area (p = 0.205) ([Table 3](#tbl0015){ref-type="table"}).Table 3Comparison of KRAS mutation rates among patients tested.Table 3Number of cases, totalKRAS mutation, n (%)Adjusted\*\* Odds Ratio 95% CIPSex Male12952 (40.3)1.00Reference (Ref)0.182 Female10451 (49.0)01.530.88--2.66Age (years) 22-39124 (33.3)1.00Ref0.693 40-6413961 (43.9)1.820.49--6.73 65+8238 (46.3)2.150.56--8.27Ethnicity Non-Hispanic White12555 (44.0)1.00Ref0.774 Hispanic9742 (43.3)0.710.33--1.51 American Indian116 (54.5)1.470.33--6.61Year of diagnosis 20105426 (48.2)1.00Ref0.628 20115320 (37.7)0.630.28--1.39 20126628 (42.4)0.750.35--1.60 20136029 (48.3)0.920.43--1.98Place of residence Urban16979 (46.8)1.00Ref0.205 Rural6424 (37.5)0.550.88--2.66Annual income, per capita (census tract) \$5,051 − \$15,6565125 (49.0)1.00Ref0.870 \$15,662 − \$23,0346126 (42.6)0.860.38--1.99 \$23,126 − \$32,0426025 (41.7)0.530.20--1.38 \$32,138 − \$84,6206026 (43.3)0.580.21--1.57

4. Discussion {#sec0040}
=============

With the advent of precision oncology, genomic testing has become the standard of care for many types of cancer. *KRAS* was among the first biomarker tests that became widely used to guide cancer treatment. ASCO and the National Comprehensive Cancer Network (NCCN) both published clinical guidelines in 2009 recommending that patients with mCRC receive *KRAS* testing of their tumors to guide the delivery of anti-EGFR therapy \[[@bib0015], [@bib0125]\]. Recent studies have shown that less than half of patients with mCRC are tested according to these guidelines [@bib0090]. Disparities in the rates of *KRAS* testing were identified in this study, with older patients and those residing in rural areas being less likely to receive testing.

Overall the rate of *KRAS* mutation in our study was 43.3% which is comparable to previous literature \[[@bib0020], [@bib0025], [@bib0030]\]. Few studies have been dedicated to exploring possible disparities in *KRAS* mutations in CRC, though some retrospective data suggest mutations are more likely to be observed in elderly patients and Asian females compared to Asian males \[[@bib0130], [@bib0135]\]. We found no differences in *KRAS* mutation rates between sex, age, ancestry, geographic or income groups.

Our findings are comparable with recent studies showing that patients living in or near a metropolitan area are more likely to receive *KRAS* testing. An evolving shortage of oncology specialists, fewer primary care physicians, and longer travel times to a cancer center likely affect access to care of those living in rural areas \[[@bib0095], [@bib0140], [@bib0145], [@bib0150]\]. With nearly 20% of CRC patients nationally living in non-metropolitan areas (over 30% in our cohort), these disparities create substantial effects. Patients living in rural areas have increased mortality rates and risk of death in CRC \[[@bib0150], [@bib0155]\]. Increased distance to an academic center and rural residency are also associated with less frequent receipt of adjuvant chemotherapy \[[@bib0150], [@bib0160], [@bib0165]\]. Our data suggests that rural residency is not only associated with treatment and outcomes disparities, but also decreased genomic testing in mCRC patients.

This study also confirms age-related disparities in cancer care. Elderly patients often do not receive guideline-concordant care in CRC. The median age of CRC diagnosis in the U.S. is 69 years, making this topic especially significant [@bib0170]. Increased prevalence of medical comorbidities and organ dysfunction in the elderly are legitimate concerns regarding the initiation of cancer treatments [@bib0170]. Schiphorst et al. demonstrated that guideline adherence for stage I--III rectal cancer in the Netherlands decreased correspondingly with age [@bib0175]. In a 2010 case vignette survey, oncologists were less likely to start chemotherapy for a patient with newly diagnosed mCRC based on advanced age alone, regardless of performance status [@bib0180]. The initiation of therapy, either for curative or palliative intent, must be weighed with the risks of adverse effects from anti-EGFR moAb therapy. Patients require monitoring for hypomagnesemia, as well as skin and gastrointestinal toxicities [@bib0170]. However, active geriatric patients with comparable functional status to younger patients with mCRC should be equally considered for anti-EGFR treatment [@bib0170].

There are several potential explanations for the finding that patients with mCRC 65 years and older do not receive *KRAS* testing. It is true that a provider may not recommend testing due to poor performance status, comorbidities, and short life-expectancy, which are more prevalent in older patients. In our study, it is unclear whether *KRAS* testing is less likely to occur as the result of discussions between patient and provider, or if the test is simply not offered. It is possible that patients with metastatic disease may refuse treatments such as anti-EGFR therapy, rendering *KRAS* status of little clinical value. Concerns about the financial burden of *KRAS* testing may also play a role in decision-making. Anti-EGFR medications range from approximately \$3000 to \$6000 cost per dose and *KRAS* testing costs approximately \$200, though both are covered by Medicare and Medicaid in New Mexico with few exceptions.

Current clinical practice guidelines indicate that *KRAS* testing should occur in mCRC patients to provide guidance on whether response to anti-EGFR therapy is expected \[[@bib0015], [@bib0125]\], though consistent adoption of *KRAS* testing remains poor. New Mexico exhibits high testing rates compared to the rest of the nation [@bib0090], though overall rates are still low, occurring in less than 40% of patients with mCRC. In contrast, a 2016 survey of 34 Kaiser Permanente oncology providers from seven centers [@bib0185] self-reported consistent ordering and rapid adoption of *KRAS* testing within 6 months of National Comprehensive Cancer Network (NCCN) guideline publication, though overall rates were not measured. While patient factors may contribute to receipt of *KRAS* testing, literature examining general adoption of cancer guidelines suggests the most important influence remains the ordering physician [@bib0190].

One source of testing inconsistency may relate to the fact that the two prominent organizations providing these guidelines have subtle differences in indications for *KRAS* testing. Per NCCN guidelines, all stage IV CRC patients should be tested, while ASCO recommends only for those being considered for anti-EGFR therapy should be offered the test. As utilizing this type of genetic analysis is a relatively new practice guideline, some oncology providers may be uncertain which guidelines to follow as well as how to interpret *KRAS* status results in order to make subsequent treatment recommendations. As research on genomic testing of tumors is generated at a fast pace, guidelines regarding testing in cancer are prone to constant modification. For example, it is now known that patients with mutations in exon 2 (codons 12 or 13) will derive no benefit from cetuximab or panitumumab and have poorer prognosis [@bib0125]. More recent ASCO guidelines have expanded to recommend tumor testing for mutations in *KRAS* exons 3 (codons 59 and 61) and 4 (codons 117 and 146) as findings from recent Phase II and III trials indicated patients with these mutations also will not benefit from anti-EGFR therapy [@bib0035]. While personalized medicine offers exciting new promise in cancer treatment, investment in education, clinical pathways prompting use, and accountability is imperative to successfully implement novel tests and clinical guidelines [@bib0190].

It is noteworthy that over one-quarter of patients tested in this cohort had non-metastatic disease, which is not recommended. While ASCO and NCCN both recommend testing of stage IV patients only, a small but developing body of literature advocates for the utility of *KRAS* testing in those with localized disease [@bib0195]. *KRAS* testing in patients with stage I through III disease is controversial and contrary to current clinical guidelines. Roth et al. reported no major prognostic value in stage II--III CRC in a multivariate analysis of 3,278 patients enrolled in an adjuvant trial \[[@bib0200]\]. Conversely, two recent studies conclude *KRAS* and *BRAF* mutations are associated with inferior survival in Japanese patients with stage I--III disease [@bib0135] and significantly poorer disease-free survival (DFS) (3-year DFS 79% and 92% in mutant and wild-type respectively; p = 0.006) [@bib0130]. Despite claims that *KRAS* status is an independent predictor of clinical outcome in resectable CRC, the aforementioned paper does not currently advocate for obtaining *KRAS* testing to guide prognosis discussions with patients. Thus, the clinical utility of obtaining *KRAS* testing in this patient population remains unclear. The high rates of testing in local and regional CRC observed in our study may stem from provider motivation to supply the patient with more information or from a misunderstanding about the current recommended use of the test. This underscores the need to further study reasons for over-testing and to guide future interventions to promote guideline-consistent care.

Our study has several limitations. The NMTR cannot ascertain whether *KRAS* testing was offered to a patient by a provider, only whether it was done or not. In regards to ancestry, American Indians were less likely to receive *KRAS* testing (28.6%) compared to non-Hispanic whites (38.8%) and Hispanics (39.8%) but this was not statistically significant. There were only 42 American Indians in our cohort, which limited statistical power. As American Indians compromise over 10% of the New Mexico population, a disparity in *KRAS* testing rates may be elucidated with more data in upcoming years.

5. Conclusion {#sec0045}
=============

Compared to national averages, New Mexico exhibits high rates of *KRAS* testing in patients with mCRC. Age and geographic testing disparities exist, while sex, ancestry and the year tested showed no significant differences. Further study is required to delineate reasons for these disparities in *KRAS* testing and survival outcomes, as well as to determine the motivation for testing in stage I through III CRC which is contrary to current guidelines.
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[^1]: \*The following characteristics had no missing values: age at diagnosis, ancestry, calendar year, sex and place of residence. Census tract data for per capita income was unavailable in two cases.

[^2]: \*\*Odds ratios adjusted for variables listed in table.
